Suppr超能文献

肺癌骨转移患者放疗后生存率分析:是否存在适宜接受高剂量放疗的最佳亚组?

An analysis of the survival rate after radiotherapy in lung cancer patients with bone metastasis: is there an optimal subgroup to be treated with high-dose radiation therapy?

机构信息

Department of Radiation Oncology, Tokai University School of Medicine, 143 Shimokasuya, Isehara, Kanagawa 259-1193, Japan.

出版信息

Neoplasma. 2012;59(6):650-7. doi: 10.4149/neo_2012_082.

Abstract

We investigated the prognostic factors after radiotherapy for bone metastasis from lung cancer while taking the recent findings in the treatment of such cases into consideration. A total of 132 patients with bone metastases from pathologically confirmed lung cancer were evaluated regarding the following potential prognostic factors: treatment for primary site (surgery vs. other), treatment site (spine vs. other), number of bone metastases (solitary vs. multiple), number of metastatic organs (0 vs. 1 vs. ≥2), neurological symptoms (no symptoms vs. numbness vs. paresis), degree of pain (no pain vs. mild pain vs. severe pain), performance status [PS] (0-1 vs. ≥2), biological effective dose [BED] (≥40 Gy vs. <40Gy), time to distant metastasis (≥1 year vs. <1 year), histology (adenocarcinoma vs. others), and use of epidermal growth factor receptor [EGFR]-targeted agents (Yes vs. No). The univariate analysis demonstrated that all factors except for the treatment site were significant. Surgery as treatment for primary site, solitary bone metastasis, no visceral organ metastasis, no symptoms or numbness, no pain, PS<2, BED≥40 Gy, time to distant metastasis ≥ 1year, adenocarcinoma histology, and use of EGFR-targeted agents were correlated with a favorable prognosis. In a multivariate analysis, solitary bone metastasis, PS<2, BED≥40 Gy, adenocarcinoma histology, and the use of EGFR-targeted agents were significantly correlated with a better survival (p = 0.038, 0.006, 0.003, 0.014, and <0.001, respectively). A contingency table to assess the relationship between each variable and the median survival time of the patients according to the administered BED showed that in patients with the time to distant metastasis ≥ 1year and the use of EGFR-targeted agents, the subgroups treated with BED≥40 Gy had a favorable prognosis. Our study suggests that high-dose radiotherapy is associated with a better prognosis in combination with other favorable prognostic factors.

摘要

我们研究了在考虑到当前肺癌骨转移治疗新进展的情况下,肺癌骨转移患者接受放疗后的预后因素。共评估了 132 例经病理证实的肺癌骨转移患者的以下潜在预后因素:原发病灶治疗(手术与其他治疗)、治疗部位(脊柱与其他部位)、骨转移灶数量(单发与多发)、转移器官数量(0 个与 1 个与≥2 个)、神经症状(无症状与麻木与无力)、疼痛程度(无疼痛与轻度疼痛与重度疼痛)、体能状态(PS)(0-1 分与≥2 分)、生物有效剂量(BED)(≥40Gy 与<40Gy)、远处转移时间(≥1 年与<1 年)、组织学类型(腺癌与其他)和表皮生长因子受体[EGFR]靶向药物的使用(是与否)。单因素分析表明,除治疗部位外,所有因素均有统计学意义。原发病灶治疗采用手术、单发骨转移、无内脏器官转移、无症状或麻木、无疼痛、PS<2、BED≥40Gy、远处转移时间≥1 年、腺癌组织学类型和 EGFR 靶向药物的使用与预后良好相关。多因素分析显示,单发骨转移、PS<2、BED≥40Gy、腺癌组织学类型和 EGFR 靶向药物的使用与生存时间改善显著相关(p=0.038、0.006、0.003、0.014 和<0.001)。根据所给予的 BED 评估患者的每个变量与中位生存时间之间的关系的列联表显示,在远处转移时间≥1 年和使用 EGFR 靶向药物的患者中,BED≥40Gy 治疗的亚组预后较好。我们的研究表明,大剂量放疗结合其他有利的预后因素与较好的预后相关。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验